Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors
NCT07490236
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Trilaciclib
CDK4/6-dependent Solid Tumors
Interventions
DRUG:
Trilaciclib group
Sponsor
Hebei Medical University Fourth Hospital